Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

NCT03640481 is registered in ClinicalTrials.gov with Kadmon, a Sanofi Company as lead sponsor.

NCT NCT03640481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03640481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Lead sponsor
Kadmon, a Sanofi Company
Phase
Phase 2
Overall status
Terminated
Start date
October 11, 2018
Completion date
December 11, 2023
Enrollment
159 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host-disease